AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today provided an update on the plans for the resubmission of the Company's New Drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE